RCAG
RNAC icon

Rehmann Capital Advisory Group’s Cartesian Therapeutics RNAC Stock Holding History

Rehmann Capital Advisory Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3
Closed -$1.46K – 2057
2018
Q3 		$1.46K Hold
3
– – ﹤0.01% 1889
2018
Q2 		$1.25K Hold
3
– – ﹤0.01% 1915
2018
Q1 		$1K Buy
+3
New +$854 ﹤0.01% 1917

Other funds holding RNAC

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rehmann Capital Advisory Group's RNAC Position: Q4 2018 in Review

Rehmann Capital Advisory Group sold out of Cartesian Therapeutics (RNAC) in Q4 2018, closing a stake of 3 shares — an estimated $1.46K sold.

Rehmann Capital Advisory Group first reported a position in RNAC in Q1 2018 and held it in 3 quarters. The position peaked at $1.46K in Q3 2018. 54 funds tracked by Wall St. Rank hold RNAC as of Q4 2018.

  • Rehmann Capital Advisory Group reported no remaining Cartesian Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 3 Cartesian Therapeutics shares in Q4 2018, an estimated $1.46K.
  • Rehmann Capital Advisory Group first reported a position in Cartesian Therapeutics in Q1 2018 and held it in 3 quarters.
  • Rehmann Capital Advisory Group's Cartesian Therapeutics position peaked at $1.46K in Q3 2018.
  • 54 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2018.

Based on Rehmann Capital Advisory Group's 13F filing for Q4 2018, filed 12 Feb 2019.